RedHill Biopharma sets 2026 shareholder meeting date

RedHill Biopharma Ltd. filed a Form 6-K to notify holders of its Annual General Meeting of Shareholders scheduled for July 28, 2026.

Rhea-AI Filing Summary

RedHill Biopharma Ltd. filed a Form 6-K to notify holders of its Annual General Meeting of Shareholders scheduled for July 28, 2026. The meeting will be held at the company’s offices in Tel-Aviv at 3:00 p.m. Israel time.

Shareholders and ADS holders of record at the close of business on June 23, 2026 are entitled to receive notice and vote. Attendees will also be able to review and ask questions regarding the company’s financial statements for the year ended December 31, 2025.

The board of directors recommends voting in favor of the proposals described in the proxy materials, and shareholders may submit written position statements by July 17, 2026 under Israel Companies Law procedures.

Key Figures

Meeting date: July 28, 2026 Meeting time: 3:00 p.m. Israel time Record date: June 23, 2026 +2 more

5 metrics

Meeting date July 28, 2026 Annual General Meeting of Shareholders

Meeting time 3:00 p.m. Israel time Annual General Meeting in Tel-Aviv

Record date June 23, 2026 ADS holders entitled to notice and vote

Financial statements period Year ended December 31, 2025 Reviewed and discussed at the meeting

Position statement deadline July 17, 2026 Last date to submit shareholder Position Statements

Key Terms

Form 6-K, American Depositary Receipts, Position Statement, Israel Companies Law, +1 more

5 terms

Form 6-K regulatory

"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

American Depositary Receipts financial

"holders of record of ADSs, evidenced by American Depositary Receipts issued"

A certificate traded on U.S. markets that represents ownership of shares in a foreign company, letting U.S. investors buy and sell that company as if it were listed domestically. Think of it as a local voucher for a foreign product: it makes price quotes in dollars, trades on familiar exchanges, and brings differences in liquidity, fees and legal protections that can affect returns and risk compared with buying the underlying foreign shares directly.

Position Statement regulatory

"Shareholders wishing to express their position ... may do so by submitting a written statement (“Position Statement”)"

Israel Companies Law regulatory

"in accordance with the guidelines set by the Israel Companies Law, will be furnished"

quorum regulatory

"If within half an hour from the time appointed for the General Meeting, a quorum is not present"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is RedHill Biopharma (RDHL) holding its 2026 annual general meeting?

RedHill Biopharma will hold its 2026 Annual General Meeting on July 28, 2026 at 3:00 p.m. Israel time. The meeting takes place at the company’s offices at 21 Ha’arba’a Street, 16th Floor, Tel-Aviv, Israel.

Who can vote at RedHill Biopharma (RDHL) July 28, 2026 general meeting?

Only holders of record of ADSs, evidenced by American Depositary Receipts issued by The Bank of New York Mellon, at the close of business on June 23, 2026 are entitled to receive notice of and vote at the General Meeting.

What will be discussed at RedHill Biopharma (RDHL) 2026 general meeting?

Shareholders will consider proposals described in the proxy materials and may review and ask questions about RedHill Biopharma’s financial statements for the fiscal year ended December 31, 2025 during the General Meeting in Tel-Aviv.

How can RDHL shareholders submit a position statement for the 2026 meeting?

Shareholders may submit a written Position Statement to the company’s offices, c/o Mr. Razi Ingber, 21 Ha’arba’a Street, Tel-Aviv, Israel, no later than July 17, 2026. Eligible statements will be furnished to the SEC on Form 6-K.

What does the RDHL board recommend for the 2026 AGM proposals?

The board of directors of RedHill Biopharma recommends that shareholders vote FOR the proposals presented for approval. The specific proposals and related details are provided in the accompanying notice and proxy materials for the General Meeting.

Where can investors find documents for RedHill Biopharma (RDHL) 2026 AGM?

The notice, related documents, and proposed resolutions will be available on RedHill Biopharma’s website at http://www.redhillbio.com and on the U.S. Securities and Exchange Commission’s website at http://www.sec.gov for public access.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 07:00 AM Learn about SEC filing dates

 UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2026
Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha'arba'a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐

Attached hereto and incorporated herein by reference is the notice of the annual general meeting of RedHill Biopharma Ltd. scheduled for July 28, 2026.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the "Registrant")
Date: June 22, 2026	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer

REDHILL BIOPHARMA LTD.
21 Ha’arba’a Street

Tel-Aviv 6473921

Israel

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

To be held on July 28, 2026

The Annual General Meeting of Shareholders of RedHill Biopharma Ltd. (the “Company”), will be held at the offices of the Company, 21 Ha’arba’a Street, 16ᵗʰ Floor, Tel-Aviv, Israel, on July 28, 2026, at 3:00 p.m. Israel time, or at any adjournments thereof (the “General Meeting”), for the following purposes:

1. To re-appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s auditors for the year 2026 and for an additional period until the next Annual General Meeting; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2025;

2. To approve the re-election of Mr. Rick D. Scruggs and Dr. Shmuel Cabilly to the board of directors of the Company (the “Board of Directors”) for an additional three-year term until the annual general meeting to be held in 2029; and

3. To approve the engagement by the Company of Mr. Dror Ben-Asher to serve as the Company's Chairman of the Board of Directors and the Company's Chief Executive Officer.

In addition, shareholders at the General Meeting will have an opportunity to review and ask questions regarding the financial statements of the Company for the fiscal year ended December 31, 2025.

The Company is currently unaware of any other matters that may be raised at the General Meeting. Should any other matters be properly raised at the General Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.

Only holders of record of ADSs, evidenced by American Depositary Receipts issued by The Bank of New York Mellon at the close of business on June 23, 2026 shall be entitled to receive notice of and to vote at the General Meeting.

The Board of Directors recommends that you vote “FOR” the proposals, as specified on the enclosed form of proxy.

ADS holders should return their proxies by the date set forth on their form of proxy.

Shareholders wishing to express their position on an agenda item for this General Meeting may do so by submitting a written statement (“Position Statement”) to the Company’s offices, c/o Mr. Razi Ingber, at 21 Ha’arba’a Street, Tel-Aviv, 6473921 Israel, by no later than July 17, 2026. Any Position Statement received, that is in accordance with the guidelines set by the Israel Companies Law, will be furnished to the U.S. Securities and Exchange Commission (the “Commission”) on Form 6-K, and will be made available to the public on the Commission’s website at http://www.sec.gov.

 If within half an hour from the time appointed for the General Meeting, a quorum is not present, the General Meeting shall be adjourned to the next business day following the day of the scheduled General Meeting, at the same time and place, or at another day, time and place prescribed by the Board of Directors in a notification to the shareholders.

This Notice and the documents mentioned therein, as well as the proposed resolutions on the agenda, will be made available to the public on the Company's website http://www.redhillbio.com and on the Commission’s website at http://www.sec.gov.

By Order of the Board of Directors,

Dror Ben-Asher

Chairman of the Board of Directors

Tel-Aviv, Israel

June 22, 2026